Implantation of SML in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy

NCT ID: NCT03882606

Last Updated: 2025-06-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-22
• Study Completion Date: 2023-09-01

Brief Summary

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in developed countries among people over 50 years of age. Myopic maculopathy is also an important cause of irreversible vision loss. Reduced near visual acuity is still a major problem with all forms of AMD and myopic maculopathy. Various intraocular lenses for near vision (IOLs) or telescopic systems have been described but are not widely accepted and almost all solutions require phakic status of the eye and are implanted during cataract surgery. Therefore, these devices are not appropriated for pseudophakic AMD and myopic maculopathy patients. Scharioth Macula Lens (SML, Medicontur) is a magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient. The implant has a bifocal optic, with a central 1.5mm diameter optical zone equivalent to +10D add and a peripheral zone optically neutral. The implantation of the add-on SML can improve the near visual acuity of pseudophakic patients with AMD and myopic maculopathy without impairing their distance visual acuity.

The principal objective is to compare the near visual acuity, the far visual acuity and the self-reported vision health status before and after the SML implantation.

Detailed Description

We present a prospective study of a cohort of patients with age-related macular degeneration and myopic maculopathy treated with SML implantation. The study was approved by the ethics committee at the Consorci Sanitari de Terassa (Barcelona, Spain).

Patients will be examined for best corrected visual acuity prior to the surgery at 6 meter and for reading at 40cm (with a +2.5D) and 15 cm (with +6D). Improvement of the reading ability at 15 cm compared to 40 cm will predict the potential for vision improvement with the add on lens.

The preoperative and postoperative assessment will include a full ophthalmological exam, visual acuity for distance and near, optical coherence tomography of the anterior chamber and of the macula, axial length and keratometry examination using biometry and VFQ25 questionnaire.

Postoperative assessment will be performed at day 1, 1 week, 1, 3 and 6 months after surgery.

Conditions

Age-Related Macular Degeneration; Lens, Intraocular; Myopic Maculopathy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SML implantation

prospective study of a cohort of patients with age-related macular degeneration or myopic maculopathy treated with SML implantation

Group Type: OTHER

Scharioth Macula Lens (SML, Medicontur)

Intervention Type: DEVICE

magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient

Interventions

Scharioth Macula Lens (SML, Medicontur)

magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Eye with better distance visual acuity or non-dominant eye in case of equal visual acuity in both eyes
• Best corrected visual acuity 0.1-0.4 (Snellen)
• Pseudophakia
• Preoperative testing of corrected near visual acuity (CNVA) at 15cm (+6 D) better than CNVA at 40 cm (+2.5D)
• understand the principle of this implant (reduced reading distance, maximum magnification)
• signing the informed consent

Exclusion Criteria

• complicated cataract surgery
• excessive zonular weakness
• chronic uveitis
• active rubeosis iridis
• central corneal opacities
• inability to understand the principle of this implant (reduced reading distance, maximum magnification)
• Narrow anterior chamber (<2.8mm)
• Narrow angle
• glaucoma
• Phakic
• Current treatment with intravitreal injections
• active maculopathy
• atrophy
• photopic pupil size less than 2.5 mm
• severe eye pathology
• previous retinal surgery

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medicontur Medical Engineering Ltd

INDUSTRY

Sponsor Role: collaborator

Consorci Sanitari de Terrassa

OTHER

Sponsor Role: lead

Responsible Party

Laura Gutiérrez-Benítez

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Consorci Sanitari de Terrassa

Terrassa, Barcelona (spain), Spain

Countries

Spain

Other Identifiers

GUTSML201902

Identifier Type: -

Identifier Source: org_study_id